SANTA CLARA, Calif. and
SALT LAKE CITY, March 28, 2012 /PRNewswire/ -- Affymetrix,
Inc. (NASDAQ: AFFX) and Lineagen, Inc., an innovative molecular
diagnostics company focused on complex, genetically linked
disorders, today announced the companies have signed an agreement
to incorporate Affymetrix' GeneChip® technology into Lineagen's
next-generation FirstStepDx, a genetic evaluation service for
individuals with developmental delay (DD), intellectual disability
(ID), and autism spectrum disorders (ASD). The new
FirstStepDx offering is anticipated to be available by mid-2012 and
will feature a proprietary microarray-based assay incorporating
novel genetic markers from recently concluded studies of more than
10,000 individuals.
(Logo:
http://photos.prnewswire.com/prnh/20111214/NY22073LOGO)
(Logo:
http://photos.prnewswire.com/prnh/20120328/NY77773LOGO )
Under the terms of the agreement, Lineagen has exclusive rights
to develop a chromosomal microarray assay based on Affymetrix'
GeneChip technology platform as part of the Powered by Affymetrix™
program. In this program, Affymetrix licenses its technology
to companies developing microarray products in a broad range of
test applications, including diagnostics. Financial terms of
the agreement were not disclosed.
"This agreement further extends our platform with Affymetrix'
technology, and we are very excited to incorporate their
robust technology into our next-generation FirstStepDx," said
Michael Paul, Ph.D., President and
CEO of Lineagen. "This next-generation FirstStepDx will
assist physicians in the diagnostic evaluation of individuals with
DD, ID, or ASD to determine genetic etiology that may influence
changes in clinical management and inform appropriate care.
The Powered by Affymetrix™ program will further ensure we can
continue to advance our breakthrough genetic testing by providing
market-leading, reproducible, and accurate results."
"We are extremely pleased to formalize a Powered by Affymetrix
partnership with an innovative company like Lineagen," said
Dara Grantham Wright, VP Global
Strategic Marketing for Clinical Applications at Affymetrix. "We
are committed to bring our technologies closer to the clinic and to
the patients who will benefit most from high quality genetic
information."
About Lineagen
Lineagen, Inc. is based in Salt Lake
City, Utah. Our mission is to accelerate and enhance the
diagnostic evaluation of medical conditions so that the best
possible outcomes can be achieved for patients and their families.
Our first commercial offering, FirstStepDx, provides physicians
with a fully integrated genetic testing, counseling, reporting, and
developmental screening service to aid in the diagnostic evaluation
of individuals with ASD or other forms of developmental delay. In
addition to our deep commitment to ASD and developmental delay, we
have ongoing scientific programs in the areas of multiple sclerosis
(MS) and chronic obstructive pulmonary disease (COPD).
For additional information, please visit www.lineagen.com.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
25,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing
facilities in Santa Clara,
Cleveland, Ohio, and Singapore. The company has about 900 employees
worldwide and maintains sales and distribution operations across
Europe, Asia, and Latin
America. For more information about Affymetrix, please visit
http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2010, and
other SEC reports for subsequent quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix
logo, GeneChip, and all other trademarks are
the property of Affymetrix, Inc.
Affymetrix, Inc.
Media Contact:
Mindy Lee-Olsen
Vice President, Marketing Services
408-731-5523
mindy_lee-olsen@affymetrix.com
Investor Contact:
Doug Farrell
Vice President, Investor Relations
408-731-5285
doug_farrell@affymetrix.com
Or
Lineagen, Inc.
Michael S. Paul
President and CEO of Lineagen
Lineagen, Inc.
801-931-6200
Justin Jackson
Burns McClellan, on behalf of Lineagen
(212) 213-0006
jjackson@burnsmc.com
SOURCE Lineagen, Inc.